Be Pharms

BePharms is a South Korean biotechnology company specializing in the development of advanced drug delivery systems (DDS) and value-added medicines. The company's core technology, the Be-Long platform, utilizes biodegradable microspheres to create long-acting injectable formulations of established therapeutic agents. This approach is designed to enhance patient compliance and therapeutic efficacy by providing sustained drug release over periods ranging from one to six months. BePharms' current pipeline focuses on high-need areas such as oncology, endocrinology, and central nervous system disorders. Their lead candidate, BP-001, is a long-acting leuprorelin formulation for prostate cancer that has reached late-stage clinical trials. By leveraging its expertise in microsphere formulation and manufacturing, BePharms aims to provide improved treatment options for chronic diseases globally.